Abstract
Anti-tumor necrosis factor (TNF) therapy has become an important alternative in the management of several chronic immunoinflammatory diseases. Three recombinant anti-TNF drugs are currently approved for clinical use in patients with various chronic inflammatory diseases such as rheumatoid arthritis, Crohn’s diseases, and severe psoriasis: (1) Remicade™ (infliximab), a mouse-human IgG1-kappa anti-TNF-alpha monoclonal antibody, (2) Enbrel™ (etanercept), a fusion protein of human TNF receptor 2 and human IgG1, and (3) Humira™ (adalimumab), a fully human IgG1-kappa anti-TNF-alpha monoclonal antibody. Two other anti-TNF-alpha antibody constructs have shown promise in pivotal phase III trials in patients with some of the same diseases: (4) Cimzia™ CDP870 (certolizumab pegol), a PEGylated Fab fragment of a humanized anti-TNF-alpha monoclonal antibody, and (5) CNTO 148 (golimumab), a fully human IgG1-kappa anti-TNF-alpha monoclonal antibody. All these proteins dramatically lower disease activity and, in some patients, may induce remission. Unfortunately, however, not all patients respond favorably to anti-TNF antibodies. Some patients either do not respond at all (primary response failure) or they respond initially but have later relapses (secondary response failure) despite increased dosage and/or more frequent administration of the drugs. The reason(s) for these response failures is(are) not entirely clear, but interindividual and even intraindividual differences in bioavailability and pharmacokinetics may contribute to the problem. Furthermore, immunogenicity of the drugs causing patients to develop anti-antibodies is a problem now recognized by many investigators, drug-controlling agencies, health insurance companies, and drug manufacturers. Monitoring of patients for circulating levels of functional anti-TNF drugs and anti-antibody development is therefore warranted so that administration can be tailored to the individual patient and so that prolonged therapies can be provided effectively and economically with little or no risk to the patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ang, H. T., and Helfgott, S. 2003. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J. Rheumatol. 30:2315–2318.
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D’ Haens, G., Carbonez, A., and Rutgeerts, P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348:601–608.
Bendtzen, K. 2003. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 61 (Suppl. 5):S6–S10.
Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., and Saxne, T. 2006. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthrit. Rheum. 54:3782–3789.
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., and Montori, V. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285.
Cheifetz, A., and Mayer, L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai J. Med. 72:250–256.
Clair, E. W., St., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., and Keystone, E. C. 2002. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:1451–1459.
Flendrie, M., Creemers, M. C., Welsing, P. M., den Broeder, A. A., and van Riel, P. L. 2003. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann. Rheum. Dis. 62 (Suppl. 2):ii30–ii33.
Grubb, R., Grubb, A., Kjellen, L., Lycke, E., and Åman, P. 1999. Rheumatoid arthritis–a gene transfer disease. Exp. Clin. Immunogenet. 16:1–7.
Gudbrandsdottir, S., Larsen, R., Sorensen, L. K., Nielsen, S., Hansen, M. B., Svenson, M., Bendtzen, K., and Müller, K. 2004. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22:118–124.
Han, P. D., and Cohen, R. D. 2004. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777.
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S., Cooley, D. A., Cohen, S. B., Gangnon, R. E., and Schiff, M. H. 2004. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31:1098–1102.
Haraoui, B. 2005. Differentiating the efficacy of tumor necrosis factor inhibitors. J. Rheumatol. Suppl. 74:3–7.
Haraoui, B., Keystone, E. C., Thorne, J. C., Pope, J. E., Chen, I., Asare, C. G., and Leff, J. A. 2004. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. 31:2356–2359.
Hennig, C., Rink, L., Fagin, U., Jabs, W. J., and Kirchner, H. 2000. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 235:71–80.
Lobo, E. D., Hansen, R. J., and Balthasar, J. P. 2004. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93:2645–2668.
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., Macfarlane, J. D., Antoni, C., Leeb, B., Elliott, M. J., Woody, J. N., Schaible, T. F., and Feldmann, M. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthrit. Rheum. 41:1552–1563.
Maini, S. R. 2004. Infliximab treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 30:329–347, vii.
Moreland, L. W. 2004. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 22:39–53.
Sandborn, W. J. 2006. What’s new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 8 (Suppl. 1):3–9.
Schellekens, H., and Casadevall, N. 2004. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251 (Suppl. 2):II4–II9.
Scott, D. L., and Kingsley, G. H. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355:704–712.
Smolen, J. S., Redlich, K., Zwerina, J., Aletaha, D., Steiner, G., and Schett, G. 2005. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin. Rev. Allergy Immunol. 28:239–248.
Solau-Gervais, E., Laxenaire, N., Cortet, B., Dubucquoi, S., Duquesnoy, B., and Flipo, R. M. 2006. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 45:1121–1124.
Svenson, M., Geborek, P., Saxne, T., and Bendtzen, K. 2007. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals – assessing serum infliximab and anti-infliximab antibodies. Rheumatology 46:1828–1834.
Svenson, M., Nedergaard, S., Heegaard, P. M. H., Whisenand, T. D., Arend, W. P., and Bendtzen, K. 1995. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur. J. Immunol. 25:2842–2850.
Tangri, S., Mothe, B. R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., Licalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174:3187–3196.
Teillaud, J. L. 2005. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opin. Biol. Ther. 5 (Suppl. 1):S15–27.
van Vollenhoven, R., Harju, A., Brannemark, S., and Klareskog, L. 2003. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. 62:1195–1198.
Vilcek, J., and Feldmann, M. 2004. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 25:201–209.
Watier, H. 2005. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin. Biol. Ther. 5 (Suppl. 1):S29–36.
Wolbink, G. J., Voskuyl, A. E., Lems, W. F., de Groot, E., Nurmohamed, M. T., Tak, P. P., Dijkmans, B. A., and Aarden, L. 2005. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64:704–707.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Bendtzen, K. (2008). Case Study: Immunogenicity of Anti-TNF Antibodies. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-75841-1_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75840-4
Online ISBN: 978-0-387-75841-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
